ALI HEALTH

241
2.9252.45% ( +0.070 )
Delay Closed: Nov 16, 16:08:11

Overview

ALI HEALTH (241)

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, an...

Open
2.855
High
2.965
Low
2.850
Prev. Close
2.855
Volume
76.26M
Turnover
223.22M
Avg Price
2.927
Bid/Ask Ratio
-16.48%
Amplitude
4.03%
52wk High
7.685
Volume Ratio
0.73
Turnover Ratio
0.47%
52wk Low
2.740
HK Mkt Cap
47.31B
Market CapHKD
47.31B
P/ETTM
21.58
P/EDynamic
21.58
P/EStatic
--
EPSTTM
0.136
EPSDynamic
0.136
EPSStatic
--
BVPS
1.25
P/B
2.34
HK Shares
16.18B
Dividend YieldTTM
7.69%
DividendTTM
0.2249
Shares
16.18B
Min lot size
2,000
Currency
HKD

ALI HEALTH Analyst Rating

View more

Forecast & Rating

Oct 27, 2026
Price forecast
HK$4.4451.74%
Forecast & RatingBuy
15analysts
  • Strong buy53.33%
  • Buy13.33%
  • Hold20.00%
  • Sell13.33%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Alibaba Health climbed roughly 2.45% today, surging 2.6% to 2.94 HKD during morning trading before paring to close at 2.925 HKD in the afternoon, with an intraday peak of 2.965 HKD recorded at 13:21 BJ time. The stock has already touched its 52-week low of 2.74 HKD, marking a 43.86% decline from the year-start price of 5.21 HKD and falling 63% below the 52-week peak of 7.91 HKD set in January, signaling bottom-forming price pressure relief. Most recent quarter (Q4 2026) delivered 9.979 billion HKD in revenue, up 14.07% year-over-year, with net profit rising 7.03% to 383 million HKD, though earnings growth is moderating. Analyst consensus price targets remain above current levels, yet China's anti-corruption campaign is disrupting pharmaceutical sales channels and hospital distribution. Valuation stands at 21.58x forward PE and 2.34x PB amid depressed pricing, with regulatory headwinds continuing to pressure earnings recovery prospects.

  2. Nov, 13

    Ali Health closed down to HK$2.855 today, declining 2.4% from the previous close of HK$2.925. The morning session remained relatively stable, briefly touching intraday high of HK$2.945 at 10:15 BJ time, but afternoon weakness set in after 1 p.m., with the stock closing below HK$2.90. On valuation and price positioning, the stock has declined approximately 45% year-to-date, slumping over 64% below its 52-week high of HK$7.91 set in mid-January, now hovering near the 52-week low of HK$2.74 from late October. Q4 revenue reached HK$9.98 billion, up 14% year-over-year, though net profit growth lags at just 7%, with net margin holding at a thin 3.8%; the P/E of 21x and P/B of 2.28x appear reasonable. At the sector level, anti-corruption measures continue to disrupt hospital sales channels, while the e-pharmacy platform also faces shifting marketing dynamics as competitors pivot toward AI, factors that may continue to weigh on the stock in the near term.

  3. Nov, 12

    Alibaba Health closed down 2.34% at HK$2.925, retreating from the previous close of HK$2.995. The stock dipped to an intraday low of HK$2.880 in morning session (10:06 BJT) before stabilizing around HK$2.895–HK$2.930 in afternoon trading through close at 16:00 BJT. The sharp decline from its 52-week high of HK$7.91 (set on January 13, 2026) underscores the stock's 63% descent; it now sits just 6.75% above the 52-week low of HK$2.74 reached in late October. Recent earnings showed Q4 operating revenue of HK$9.98 billion (+14.07% YoY) and net profit of HK$381 million (+7.03% YoY), suggesting underlying business momentum persists. However, analyst consensus target sits above spot, yet the stock has struggled to sustain upside momentum. With a market cap near HK$47 billion and turnover rate of just 0.52%, trading liquidity remains thin.

  4. Nov, 11

    Alibaba Health's Hong Kong-listed shares slipped approximately 2% to close at HK$2.995 today, reflecting profit-taking momentum following recent strength. The stock opened at HK$3.020 during the morning session at 09:30 before declining to HK$3.010 by 11:59, then continued lower in the afternoon session, sliding to a low of HK$2.980 at 15:39 before a modest recovery. Despite today's pullback, analyst consensus targets remain positioned above the current spot price, underscoring market support for the company's fundamentals. Fourth-quarter earnings released recently show revenue of HK$9.979 billion, up 14.07% year-over-year, with net profit of HK$380.5 million climbing 7.03% compared to the prior-year quarter, demonstrating steady earnings growth and a net margin of 3.81%. From a valuation perspective, while the stock has declined 42.51% year-to-date and sits 62% below its 52-week high of HK$7.91 reached in January, it now trades only 9.31% above October's 52-week low of HK$2.74, suggesting a potential stabilization after the steep selloff. The company carries a market capitalization of HK$48.4 billion, offers a dividend yield of 7.51%, and recently convened a special general meeting, signaling potential positive developments ahead.

  5. Nov, 10

    Ali Health closed virtually flat at HKD 3.055 (+0.33%) today, with morning weakness down to HKD 3.035 followed by afternoon rebound, signaling renewed investor interest as the stock rebounds from its late-October 52-week low of HKD 2.74 (+11.5% since). On fundamentals, Q4 operating revenue reached HKD 9.979 billion with solid 14.07% YoY growth, yet net profit expanded only 7.03% and net margin remained thin at 3.81%, suggesting top-line expansion faces headwinds in profit conversion. From a valuation lens, the stock has tumbled 41.36% year-to-date and trades 61.38% below its 52-week high, but has clearly recovered above both 20-day (2.926) and 60-day (2.981) moving averages, indicating technical stabilization. Recent research consensus targets exceed current levels, and the special general meeting announcement has sparked speculation around potential catalysts. However, the subdued net margin and modest ROE of 7.5% suggest valuation re-rating faces structural headwinds.

News

Bullish vs. Bearish — Last 3 Months

24.0k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • M
    momoM

    $XTALPI(02228.HK) Goldman Sachs launched the "China AI Healthcare Index" today, with Pharmaron as the top-weighted stock $ALI HEALTH(00241.HK)$JD HEALTH(06618.HK)$PA GOODDOCTOR(01833.HK)$YIDU TECH(02158.HK)$MircroPort Medbot-B(02252.HK)

    图片 1,共 1 张